Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The US National TOP Registry is a clinical study aimed at understanding how well donor lungs perform after being preserved and evaluated using a special device called the OCS Lung System. This study will gather important information about the outcomes of lung transplants, both in the short term and over a longer period, to see how effective this device is in real-life situations since it was approved by the FDA for use in the United States.
If you or a loved one is a lung transplant recipient, you may be eligible to participate in this study, which welcomes all individuals who have received a lung transplant. Participants will help researchers collect data that could improve future lung transplants and the use of the OCS device. In this trial, you can expect to provide information about your health and recovery, helping to shape the future of lung transplantation. Your contribution could be invaluable in enhancing the care and outcomes for future lung transplant patients.
Gender
ALL
Eligibility criteria
- • All lung transplant recipients
About Transmedics
TransMedics is a pioneering medical technology company focused on transforming the organ transplant process through innovative solutions. With a commitment to improving patient outcomes, TransMedics has developed advanced organ preservation and transportation systems, notably the Organ Care System (OCS), which enables the preservation and assessment of donor organs in a more physiologically relevant environment. By leveraging cutting-edge technology, TransMedics aims to enhance the viability of organs for transplantation, ultimately expanding the donor pool and improving the lives of patients awaiting transplants. The company’s dedication to research and clinical trials underscores its mission to advance the field of transplantation and contribute to better healthcare solutions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Minneapolis, Minnesota, United States
Milwaukee, Wisconsin, United States
Durham, North Carolina, United States
Phoenix, Arizona, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported